Type :
Anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. It specifically binds to the eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programmed death).
Status :
PharmaMar on April 28 said it launched the Phase II APLICOV-PC clinical trial of Aplidin in patients with COVID-19 following authorization by the Spanish Medicines and Healthcare Products Agency (AEMPS). The multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission.
Three hospitals in Madrid will participate in the study. During the study’s first stage, 27 patients will be recruited, to whom three doses will be administered. The viral load of the patients will be measured before and after the treatment, as well as a series of other parameters for clinical evolution. If results are positive, the trial would continue at the optimal dose after discussion with the regulator, with a larger cohort of patients.
